Twist Bioscience Corporation reported a revenue increase of 16.9% for the first quarter of fiscal 2026, with total revenues reaching $103.7 million, up from $88.7 million in the same period last year. This growth was primarily driven by a 27.4% increase in revenue from DNA synthesis and protein solutions, which generated $51.1 million, and a 8.2% rise in NGS applications, contributing $52.6 million. Despite the revenue growth, the company recorded a net loss of $30.5 million, slightly improved from a net loss of $31.6 million in the prior year.

The company's financial performance showed a gross margin increase to 52.0%, up from 48.3% in the previous year, attributed to higher revenues and cost-saving initiatives. Total costs and expenses rose to $136.6 million, compared to $123.4 million in the same quarter of 2024, largely due to a 24% increase in selling, general, and administrative expenses, which reached $69.7 million. Research and development expenses decreased by 20% to $17.1 million, reflecting cost management efforts following the sale of its DNA digital data storage business.

Operationally, Twist Bioscience expanded its customer base, serving approximately 2,538 customers in the latest quarter, up from 2,376 a year earlier. The number of genes shipped also increased significantly, with approximately 271,000 genes shipped compared to 205,000 in the same quarter of 2024, marking a 32.2% rise. The company continues to leverage its proprietary DNA synthesis technology, which has been pivotal in its growth strategy, allowing for enhanced product offerings and operational efficiencies.

As of December 31, 2025, Twist Bioscience reported cash and cash equivalents of $148.6 million, alongside short-term investments of $49.4 million, providing a total liquidity position of $197.9 million. The company anticipates that its current cash reserves will be sufficient to fund operations for at least the next year. Looking ahead, Twist Bioscience aims to continue its focus on expanding its product lines and market presence, particularly in the synthetic biology and biologic drug sectors, while managing operational costs effectively to move towards profitability.

About Twist Bioscience Corp

Twist Bioscience specializes in synthetic DNA and RNA manufacturing using proprietary silicon-based platform technology. Its core products include synthetic genes, oligonucleotide pools, NGS tools, and antibody libraries, serving global research, healthcare, and industrial markets. The company enables applications in drug discovery, diagnostics, materials, agriculture, and data storage, offering high-quality, scalable, and cost-effective solutions with a focus on innovation, sustainability, and regulatory compliance.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.